Company: IOBT
Filing Date: 2025-08-11
Form Type: 8-K
Source: 0001193125-25-177471
Chunk: 0

Company: IO Biotech, Inc.
Filing Date: 2025-08-11
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02.      Results of Operations and Financial Condition.  

As discussed below, IO Biotech, Inc., a Delaware corporation (the “ Company”), is hosting a conference call and webcast, during which the Company will make a slide presentation. In the slide presentation, the Company is disclosing an estimated cash and cash equivalents balance of approximately $28.1 million as of June 30, 2025, and further disclosing that the Company estimates that these cash and cash equivalents, plus the €12.5 million drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank, will be sufficient to meet its working capital requirements into the first quarter of 2026.

Because the Company’s financial closing procedures as of and for the six months ended June 30, 2025, are not yet complete, its final results upon completion of those procedures may differ materially from its preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.